The Arizona Department of Health Services (ADHS), through the Arizona Biomedical Research Centre (ABRC), will be opening a solicitation approximately thirty (30) days from the publication of this notice for the acceptance of grant applications to conduct clinical trials on the efficacy of Psilocybin Whole Mushrooms on various conditions, disorders, and diseases.
This announcement serves as the notice required pursuant to by Laws 2023, Chapter 139 (56th Leg 1st Reg), SB 1726, Sec. 6(B)1
(https://www.azleg.gov/legtext/56leg/1R/laws/0139.pdf).
Once the solicitation period is open, access to the funding opportunity can be found at https://grants.az.gov/funding-opportunities. Applications can be submitted using the eCivis Grant Portal. Applicants may establish an account on the eCivis portal in advance of the opening of the solicitation. This can be done on the following website: https://portal.ecivis.com.
The Arizona Legislature has appropriated up to $5,000,000 during fiscal year 2023-2024 to fund phase one (1), two (2), and/or three (3) clinical trials. These clinical trials must be capable of approval by the United States Food and Drug Administration (FDA) and authorization by the United States Drug Enforcement Administration through certification of Schedule 1 Research of Psilocybin, for evaluating the effects of whole mushroom psilocybin in the treatment of any of the following conditions, disorders, or illnesses:
- Post-Traumatic Stress Disorder,
- Symptoms associated with long COVID-19,
- Depression,
- Anxiety disorders,
- Symptoms associated with end-of-life distress,
- Obsessive compulsive disorders,
- Substance abuse and addiction disorders,
- Eating disorders,
- Chronic pain,
- Inflammatory disorders,
- Autoimmune disorders,
- Seizure disorders, and
- Other degenerative disorders.
Any clinical trials that are funded pursuant to this announcement and subsequent grant solicitation shall prioritize: using whole mushroom psilocybin cultivated under a Schedule I license for research, issued by the United States Drug Enforcement Administration; and using veterans, first responders, frontline health care workers and persons from underserved communities as the research subjects.
Applications received will be reviewed by a team of peer reviewers who will forward their recommendations to the Psilocybin Research Advisory Council, established pursuant to Laws 2023, Chapter 139 (56th Leg 1st Reg),SB 1726, Sec. 6(F)2, for consideration of the recommendations and to forward their award recommendation to the Director of ADHS by approximately February 1, 2024.
John Garcia, MBA
ABRC Program Director
Arizona Department of Health Services
——————————-
1ADHS shall announce the opening of the application process at least thirty days before applications are available and allow at least thirty days for applicants to complete their submission,” Laws 2023, Chapter 139 (56th Leg 1st Reg),SB 1726, Sec. 6(B), https://www.azleg.gov/legtext/56leg/1R/laws/0139.pdf).
2The advisory council shall: establish criteria for the clinical trials that qualify to receive research grants; oversee the application process and review applications for the clinical trial research grants; to assist the director in selecting the most credible clinical trials to award the research grants; and ensure that all advisory council meetings are open to the public and to allow for public testimony.
For more information, please contact the Arizona Biomedical Research Centre
John S. Garcia, MBA, CPM
Program Director
E-mail: biomedical@azdhs.gov
Website: https://azdhs.gov/biomedical